Colorectal cancer remains one of the deadliest cancers globally—third in incidence, second in mortality. Standard treatment usually includes a mix of surgery, chemotherapy and sometimes radiation. Once the initial battle is won, patients are typically handed a broad set of guidelines: eat well, move more, stay vigilant. But a new study suggests we may need to get far more specific—because exercise isn’t just helpful, it might be life-saving.
A sweeping clinical trial, quietly unfolding over the last 15 years across Canada, Australia, the US, the UK, and France, has now revealed that people who committed to a supervised exercise routine after colon cancer treatment saw a 28% drop in cancer recurrence—and a staggering 37% reduction in death from any cause. Notably, this wasn’t a group of athletes. Most participants were overweight, many had never exercised consistently, and their ages ranged from young adulthood to the cusp of 85.
Published in The New England Journal of Medicine, the findings emerge from the CHALLENGE trial—a name that turned out to be fitting. For three years, nearly 900 patients were split into two camps: one received general health education, the other committed to a structured, coached fitness plan. We’re not talking marathons—just the equivalent of three to four brisk walks a week, paced with a physical activity consultant. The results speak volumes.
By the time researchers tallied data almost eight years later, the contrast was undeniable. In the exercise group, just under 21% experienced a recurrence, new cancer, or death, compared to nearly 30% in the health advice group. Disease-free survival at five years? Over 80% for the active group versus less than 74% for the rest.
The results prompted some experts to wonder: Is this the new gold standard in post-cancer care?
“This is excellent news,” said Dr. David Sebag-Montefiore, a clinical oncology professor in the UK, who wasn’t involved in the study. “Exercise gives us all the benefits without the toxic fallout we see from many cancer drugs.”
Dr. Julie Gralow of the American Society of Clinical Oncology echoed the sentiment—with a note of caution. “I’m not saying we should toss the drugs aside,” she clarified. “But the degree of benefit we’re seeing here is comparable—and without the side effects.”
So how exactly does walking compare to a prescription drug? According to lead researcher Dr. Kerry Courneya at the University of Alberta, it’s not just about recurrence. Exercise improves fatigue, mood, strength, and even heart health. “And unlike medication, its side effects are basically all positive,” he said. Plus, it’s a bargain: the entire intervention cost between 3,000 to 5,000 Canadian dollars, a drop in the bucket compared to cancer drugs that can exceed $100,000.
Of course, scaling this kind of intervention has its hurdles. Clinics are already strained. Weekly or even monthly visits to exercise consultants may not be feasible everywhere. But the message is clear: movement matters, and systems need to adapt.
“We need to find ways to embed this into routine care,” said Dr. Vicky Coyle from Queen’s University Belfast, one of the study’s lead investigators. “That might mean digital coaching, community programs, or training oncologists to issue exercise prescriptions.”
There are still questions. Will patients stick with the regimen without direct oversight? Can virtual tools replicate in-person guidance? And perhaps most importantly, will insurance systems get on board?
For now, though, one thing is certain: a good pair of walking shoes may belong right next to your pillbox.
